



Comparative analysis of the AIB1 interactome in breast cancer
reveals MTA2 as a repressive partner which silences E-Cadherin to
promote EMT and associates with a pro-metastatic phenotype
Damir Varešlija 1 ● Elspeth Ward 1 ● Siobhan P. Purcell1 ● Nicola S. Cosgrove1 ● Sinéad Cocchiglia 1 ●
Philip J. O’Halloran2 ● Sara Charmsaz1 ● Fiona T. Bane1 ● Francesca M. Brett3 ● Michael Farrell3 ● Jane Cryan3 ●
Alan Beausang3 ● Lance Hudson1 ● Arran K. Turnbul4 ● J. Michael Dixon4 ● Arnold D. K. Hill1 ● Nolan Priedigkeit5 ●
Steffi Oesterreich 5,6 ● Adrian V. Lee 5,6,7 ● Andrew H. Sims 8 ● Aisling M. Redmond9 ● Jason S. Carroll 9 ●
Leonie S. Young 1
Received: 13 May 2020 / Revised: 20 October 2020 / Accepted: 7 December 2020
© The Author(s) 2021. This article is published with open access
Abstract
Steroid regulated cancer cells use nuclear receptors and associated regulatory proteins to orchestrate transcriptional networks
to drive disease progression. In primary breast cancer, the coactivator AIB1 promotes estrogen receptor (ER) transcriptional
activity to enhance cell proliferation. The function of the coactivator in ER+ metastasis however is not established. Here we
describe AIB1 as a survival factor, regulator of pro-metastatic transcriptional pathways and a promising actionable target.
Genomic alterations and functional expression of AIB1 associated with reduced disease-free survival in patients and
enhanced metastatic capacity in novel CDX and PDX ex-vivo models of ER+ metastatic disease. Comparative analysis of
the AIB1 interactome with complementary RNAseq characterized AIB1 as a transcriptional repressor. Specifically, we report
that AIB1 interacts with MTA2 to form a repressive complex, inhibiting CDH1 (encoding E-cadherin) to promote EMT and
drive progression. We further report that pharmacological and genetic inhibition of AIB1 demonstrates significant anti-
proliferative activity in patient-derived models establishing AIB1 as a viable strategy to target endocrine resistant metastasis.
This work defines a novel role for AIB1 in the regulation of EMT through transcriptional repression in advanced cancer cells
with a considerable implication for prognosis and therapeutic interventions.
Introduction
Breast cancer metastases arising from luminal tumors have
been poorly understood despite representing the most com-
mon molecular subtype. The shift to a metastatic phenotype
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encompasses dynamic and progressive alterations in key
(epi)-genetic and transcriptomic processes occurring in the
face of dysregulated steroid hormone signaling [1]. Primary
luminal breast tumors typically express estrogen receptor
(ER) and are reliant on nuclear receptors and transcriptional
coregulators to operate key nodes required for the crosstalk
between endocrine and growth factor signaling [1]. Given that
the pro-proliferative transcriptional response is self-sustaining
in the absence of steroids, understanding the regulatory
machinery driving the transition to endocrine therapy resis-
tance and a switch to metastatic tumor formation becomes
essential.
Endocrine therapy resistant tumor cells can frequently
undergo adaptive transcriptional reprogramming resulting
in the diminished dependence on steroid hormone signaling
[2–4]. Other growth and survival mechanisms may there-
fore emerge in many cases even if ER remains expressed,
but where its activity is bypassed. Our previous work
identified steroid receptor coactivator, AIB1 (SRC3,
NCOA3), as a key determinant of the adaptive response in
endocrine resistance [2, 5]. AIB1 is frequently amplified
and over-expressed in a number of epithelial tumors [6].
Altered expression of AIB1 in breast cancer contributes to
tumor initiation and progression [5, 7, 8] and has been
specifically associated with the early survival of cells that
have acquired endocrine resistance [2]. In addition, previous
work has suggested that the advanced endocrine resistant
metastatic phenotype appears to be less dependent on ER
and its transcriptional program [2, 5]. These prior obser-
vations support the idea that in endocrine resistant tumors,
AIB1 may not act exclusively via ER and its association
with other factors likely explains its continued function in
metastasis.
The pro-metastatic AIB1-interacting network is poorly
characterized and the mechanism that bypasses ER activity
and employs AIB1 in the metastatic phenotype in endocrine
resistant disease remains unknown. To shed light on these
issues, we establish that AIB1 acts a key survival factor in
advanced breast cancer models where it activates tran-
scriptional programs associated with endocrine resistance.
We use rapid immunoprecipitation mass spectrometry of
endogenous proteins (RIME) to define the AIB1 inter-
actome mediating a pro-metastatic phenotype under endo-
crine resistant conditions. We demonstrate that AIB1 can
interacts with MTA2 to form a repressive complex, inhi-
biting CDH1 (encoding E-cadherin) to promote EMT and
drive progression in ER-positive luminal tumors. Con-
sequentially, AIB1 may represent a promising therapeutic
opportunity in the metastatic phase of endocrine resistant
disease. These findings emphasize the importance of AIB1
in ER+ metastatic breast cancer pathology and establish
AIB1-dependent functions as a key molecular determinant
of metastatic competence.
Results
AIB1 is enriched in endocrine resistant and
metastatic tumors where it associates with poor
outcome
Associations between aberrant expression of AIB1 and poor
prognosis in ER+ breast tumors have been previously
reported by our group and others [5, 9, 10]. Consistent with
these studies, here, in extended cohorts of endocrine therapy
treated populations, we observed worse distant metastasis
free survival in tamoxifen treated patients and reduced
breast cancer specific survival in AI treated patients har-
boring high AIB1 mRNA expression (P= 0.0002, N= 669;
P= 0.0004, N= 70, respectively) (Figs. 1A, B; S1A, B).
Associations of elevated AIB1 mRNA with worse overall
survival were further validated in ER+ tumors from the
METABRIC cohort (P= 0.0259; N= 1825) (Fig. S1C,
Supplementary Table S1a). Given the lack of knowledge
regarding the contribution of AIB1 in ER+ metastasis, we
interrogated an additional independent cohort of ER+
patients receiving endocrine treatment in the metastatic
setting. Here, high AIB1 expression associated with worse
progression-free survival in the advanced patient population
(P= 0.000001, HR= 3.6, n= 100) (Fig. 1C).
In addition we investigated the frequency of AIB1
genomic alterations in the publically available Metastatic
Breast Project and the Lefebvre et al. metastatic cohorts
(N= 453) [11]. AIB1 amplifications/mutations were detec-
ted in 6% of tumors and are displayed alongside genes
found frequently mutated in metastatic patients, including
ESR1, PI3KC and ERBB2 [12–14] (Fig. 1D, Table S1b).
Of interest, the majority of AIB1 genomic alterations were
found to be independent of ESR1, ERBB2 or PI3KC
mutations (co-occurrence tendency with AIB1: P= 0.536,
P= 0.543, and P= 0.385 respectively) (Fig. 1D, Table S2).
This lack of coassociation between ESR1 and AIB1-
driven metastatic tumors was further substantiated in the
analysis of Siegel et al. RNA-seq of ER+ primary breast
tumors and matched metastasis from multiple organs (N= 6
patients; N= 32 tumors) [15]. Here, while ESR1 expression
is not routinely maintained, the metastatic tumors (including
lung, liver, lymph nodes, and adrenal) consistently sustain
or harbor increases in AIB1 mRNA expression in compar-
ison with the primary tumors (P= 0.0329) (Fig. 1E). To
corroborate these observations we analyzed RNA-seq data
in our cohort of longitudinal ER+ patient–matched pri-
maries and metastatic tumors (bone and brain; n= 34),
where we observe a decrease in ESR1 expression
(P= 0.0371) and its target gene GREB1 (P= 0.0137) on
metastasis, with no loss detected in AIB1 mRNA expression
(P= 0.097) (Fig. S1D). Moreover, genome-wide analysis
of transcriptionally activating H3K4me3 mark in endocrine
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resistant metastatic tumors by ChIP-seq [16] (n= 10)
revealed enhanced activity at AIB1 loci in bad outcome
versus good outcome metastatic tumors (Fig. S1E). Col-
lectively, these findings demonstrate a clear association
between high AIB1 mRNA expression and poor outcome in
endocrine therapy treated ER+ tumors that carries into the
metastatic setting.
Inhibition of AIB1 function demonstrates significant
anti-tumor activity in endocrine resistance
To investigate the contribution of AIB1 in ER+ metastasis
we utilized endocrine resistant LY2 cells that form metas-
tases following both mammary fat pad implantation [3] and
intracardiac injection. LY2 cells are resistant to both
tamoxifen and insensitive to the selective ER degrader,
fulvestrant, in vitro and ex vivo (Fig. S2A, B). Through
multiple rounds of intracardiac injections, we established
metastatic sub-lines of LY2 cells that colonized the chest-
wall, liver, lung, and bone (Fig. 2A). Alongside their par-
ental LY2, all sublines expressed AIB1 and pAIB1Thr24
protein with varying levels of expression of ER (Fig. 2B).
Previous studies have reported on a new class of potent
small molecule inhibitor against AIB1, SI-2 [17]. SI-2 has
been shown to selectively target protein levels of AIB1 and
its transcriptional activity with effective activity in vivo and
minimal toxicity observed [17, 18]. Using LY2-LUC cells
and each of the corresponding metastatic sub-lines we were
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Fig. 1 AIB1 predicts outcome in endocrine resistant breast cancer.
A Ranked AIB1 target gene set expression in 669 primary breast tumors
from ER positive Tamoxifen-treated patients. Kaplan–Meier analysis of
distant metastatic free survival (DMFS) according to mRNA expression of
AIB1 in ER positive 4-OHT-treated patients (n= 669). Data is from four
published Affymetrix microarray datasets (GSE6532, GSE9195,
GSE17705, GSE12093). B Ranked AIB1 expression in primary breast
tumors from ER positive AI-treated patients. AIB1 mRNA expression
associated significantly with worse breast cancer specific survival (BCS)
(p= 0.0004, n= 70, HR 4.7). Data is from published Affymetrix micro-
array datasets (GSE55374/GSE20181). For both colors are log2 mean-
centered values, blue=high, orange=low. All data sets were summarized
with Ensembl alternative CDF and normalized with Robust Multi-array
Average (RMA), before integration using ComBat to remove dataset-
specific bias. C Ranked AIB1 expression in metastatic breast tumors from
ER+ AI-treated patients. Kaplan-Meier displays high AIB1 expression
associating with worse progression-free survival (p= 0.000001,
n= 100) in metastatic ER+ AI-treated patients. Data is from published
Affymetrix microarray dataset GSE41994. Colors are log2 mean-centered
values, blue=high, orange=low. All data sets were summarized with
Ensembl alternative CDF and normalized with Robust Multi-array Aver-
age (RMA), before integration using ComBat to remove dataset-specific
bias. D cBioPortal generated oncoprint map displaying most common
amplifications/mutations detected in DNA-sequenced metastatic breast
tumors from the Metastatic Breast Cancer Project and Lefebre et al cohort
(n= 453). Oncoprint map is cropped to highlight first 100 tumors that
capture AIB1 aberrations in relation to other frequently altered genes (Full
annotation can be found in Supplement Tables). E Paired ladder plot of
AIB1 and ESR1 mRNA expression in patient-matched primary (P) and
metastatic (M) cases (n= 6 patients; n= 32 tumors; Siegel et al.). Light
green dots represent primary tumor expression values and dark green dots
represent metastatic tumor expression values (log2norm CPM). P value
obtained via two-sided Wilcoxon signed-rank test.
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able to demonstrate that treatment with an AIB1 inhibitor,
SI-2, can reduce expression of both total AIB1 and
pAIB1Thr24 (Fig. 2C). Indeed, short-term (96 h) treatment of
endocrine resistant metastatic sub-lines with SI-2 demon-
strated a significant decrease in cell viability compared to
vehicle or endocrine treatment alone (Fig. 2D). Moreover,
SI-2 treatment appears more efficacious compared to both
fulvestrant and palbociclib in LY2-LUC and LY2-
LUCLung_Met, while performing comparably in LY2-
LUCBone_Met (Supplementary Fig. S2C). Given that AIB1
is a mediator of endocrine treatment resistance we find that
inhibition of AIB1 by knockdown in resistant metastatic
Fig. 2 AIB1 can be targeted in models of metastatic disease. A
Schematic representation of the in vivo isolation of the metastatic
endocrine resistant cells. LY2-Luc cells were disseminated via intra-
cardiac injection into NOD-SCID mice. At the end of experiment the
metastatic cells were confirmed by IVIS bioluminescence imaging (BLI)
in vivo and ex vivo. Metastatic colonising cells from chest-wall, liver,
lung, and bone were isolated, briefly cultured and injected 3 more times.
These cells were once again isolated and metastatic variants were
established in culture. Representative images with indicated BLI readings
and scale are displayed for in vivo and ex vivo imaging alongside 20x
FITC (fluorescein isothiocyanate) microscopy images of early cultured
GFP+ ve cells. B Western blotting of AIB1, pAIB1, ER, and TBP
protein expression in the nuclear lysates of various endocrine resistant
metastatic variants under estrogen deprived conditions. C AIB1 and
pAIB1 western blots 48 h post treatment with 50 nM of AIB1 inhibitor
SI-2. D Cells were treated for 96 h with vehicle (DMSO), 4-OHT (10-
7M) or SI-2 (50 nM) under estrogen deprived conditions. E Cells were
transfected with either siNT-1 or siAIB1-1 and cell viability assay was
carried out in the presence of either vehicle or 4-OHT (10-7M). Cell
viability was measured using an MTS assay and graph display % cell
viability relative to vehicle. F Cells were transfected with either siNT-1
and siNT-2 or siAIB1-1 and siAIB1-2. Cell proliferation was measured
after 5 days. Graphs display % proliferation relative to siNT.G AIB1 and
pAIB1 western blots 48 h post transfection with siNT-1, siNT-2, siAIB1-
1, or siAIB1-2. H Colony forming assay was carried out with cells
seeded under estrogen depleted conditions and treated with DMSO or
50 nM SI-2 every 3 days for a total of 14 days. Representative images of
the cells stained with crystal violet at day 14. I T347 primary culture cell
line was treated for 96 h with vehicle (DMSO), 4-OHT (10-7M) or SI-2
(50 nM). T347 cells were transfected with either empty pcDNA3.1
plasmid vector (Control) or pcDNA3.1 plasmid containing full-length
AIB1 (AIB1_OVX) which were both treated with DMSO and SI-2
(50 nM) for 96 h and cell viability measured. Graph displays % cell
viability relative to Vehicle control. Western blot analysis of AIB1 and
TBP. All experiments are representative of three biologically indepen-
dent replicates. Western blot gel images are cropped at the band of
interest for clarity. Two-sided t-tests were used to calculate P values
(***P < 0.0001).
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cells LY2-LUCLUNG_METS is sufficient to induce a re-
sensitization of resistant cells to 4-OHT (Fig. 2E).
In addition, using two independent siRNAs directed
against AIB1 we observe a significant reduction in cell
proliferation in most of the endocrine resistant metastatic
sub-lines (Fig. 2F) with a noted downregulation in protein
levels of AIB1 and pAIB1Thr24 (Fig. 2G). The impact of
AIB1 inhibition on cell growth of metastatic sub-lines was
even more pronounced over a 14 day treatment as evi-
denced by colony forming assay (Fig. 2H). Using LY2-
LUC model we demonstrate that a knockdown of AIB1 can
diminish the effectiveness of SI-2 inhibition suggesting
specific action against AIB1 (Supplementary Fig. 2D). This
is further substantiated by the lack of response to SI-2
observed in the ER+ve endocrine resistant T347 cell line
model (AIB1 low protein expression), which can be
induced with AIB1 overexpression (Fig. 2I). Taken
together, these observations reinforce the continued invol-
vement of AIB1 in endocrine resistant metastatic setting.
Next, we evaluated the impact of targeting AIB1 in
several ER+ metastatic patient-derived xenografts (PDXs)
[19–21] that model clinically relevant endocrine resistant
tumors (Table S3). PDXs were engrafted from metastatic
tissue and used to further establish patient-derived tumor
explants (PDTEs) (Fig. 3A). Tumor tissue from five PDTEs
with varying AIB1 protein positivity scores was treated with
50 nM of AIB1 inhibitor SI-2 for 72 h and the proliferation
index measured (Fig. 3B). SI-2 treatment inhibited tumor
proliferation and pAIB1Thr24 protein expression in high
pAIB1 models including T638 PDTE (ki67% inhibition
44%; P= 0.055), HCI-05 PDTE (ki67% inhibition 82%;
P= 0.032) and HCI-11 PDTE (ki67% inhibition 63%; P <
0.001), but not the low pAIB1-expressing T347 and T328
PDTE model (Fig. 3C and D, Supplementary Fig. 3A). By
Fig. 3 Inhibition of AIB1 demonstrates significant anti-tumor
activity in endocrine resistant patient-derived metastatic samples.
A Schematic indicates establishment protocol for patient-derived xeno-
grafts (PDXs) and subsequent patient-derived tumor explants (PDTEs).
B Schematic of the ex vivo PDTE experiment set up. Immunohis-
tochemistry (IHC) protein analysis of AIB1 and ER in PDX models
established from metastatic endocrine resistant patient samples. Various
PDXs were confirmed to have variable levels of AIB1 protein expres-
sion. H score is displayed and was quantified from three biologically
independent samples. At least 500 cells were assessed in each case. C
PDTEs were treated with DMSO or 50 nM SI-2 and processed as
described. Bar chart displays ki67% determined from manual counts of
ki67 positive cells over total number of cells. Representative images of
IHC analyses of Ki67 tumors treated for 72 h with indicated treatments.
Zoomed in images of ki67+ve representative areas of worst responder
PDTE T347 and best responder HCI-11. All scale bars represent 50 μm.
Error bars represent mean ± s.e.m. (n= 4–6 images per group). D Bar
chart displays % pAIB1Thr24(pAIB1) positivity relative to DMSO
determined by Aperio ImageScope positive pixel algorithm. Repre-
sentative IHC images of pAIB1 in DMSO and SI-2 treated samples.
Two-sided t tests were used to calculate P values. All scale bars, 50 μm.
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analyzing pAIB1Thr24 levels for T638, T347, HCI-11, and
HCI-05 in DMSO versus SI-2, we observe a significant
reduction in the levels of pAIB1 in the responder tumor
explants (Fig. 3D). In the case of tumor explant T638 where
we had sufficient tissue sections, we also profiled AIB1 and
pERSER118 and we observe a significant reduction in total
AIB1 levels but not pERSER118 (Supplementary Fig. 3B).
Similarly, to the LY2-LUCLUNG_METS, a targeted
approach utilizing SI-2 in the PDTE T638 is sufficient to
induce re-sensitization of resistant tumor to antiestrogens
(Supplementary Fig. 3C). Together, these data underpin the
significance of AIB1 in endocrine resistant ER+ metastatic
breast cancer pathology and substantiate the potential of
AIB1 as a therapeutic target in advanced disease.
AIB1-dependent transcriptome and interactome as
potentiators of the pro-metastatic phenotype
Having observed the transcriptomic/genomic divergence
between AIB1-driven tumors and its known partnering fac-
tors, it was important to define the mechanism behind pro-
metastatic phenotype potentiated by AIB1. To do this we
utilised the endocrine resistant cell models that express AIB1
and respond to pharmacological AIB1 inhibition under
estrogen-deprived conditions (Figs. 4A, S4A, B). Given that
we saw the most significant clinical association of high AIB1
expression and metastatic progression in AI-treated patient
models, we decided to further investigate AIB1 in the AI-
resistant, LetR cells. LetR cells were established from the
Fig. 4 AIB1 transcriptome and interactome in the endocrine
resistant cells acts as a regulator of pro-metastases pathways. A
Scatter plot graph displays % cell viability after 96 h of multiple endo-
crine resistant cell line models (under estrogen deprived conditions) in
the presence of vehicle (DMSO) or AIB1 inhibitor SI-2 (50 nM). All
results are mean ± S.E.M., n= 3 and two-sided t tests were used to
calculate P values (***P < 0.0001). B Schematic of the RNA-seq
experimental design. RNA-seq was carried out in biological triplicate in
MCF7 and LetR cells comparing NT (Scramble siRNA) cells versus
cells depleted of AIB1 using a SMARTpool ON-TARGETplus siRNA.
C Venn diagram displays the number of differentially expressed genes
(DEGs) identified with AIB1 knockdown in MCF7 versus LetR cells
(logFoldChange ± 1.5, Padj ≤ 0.05). D Graph displays MsigDB Onco-
genic signature gene pathways enriched in AIB1-dependent DEGs spe-
cific to LetR cells. Also displayed are P values and Z scores for reach
significant pathway identified. E Schematic representation of the
experimental design for Rapid Immunoprecipitation of Endogenous
(RIME) AIB1. AIB1 RIME was conducted in MCF-7 and LetR cells
under estrogen deprivation conditions (n= 3 biological replicates).
Nonspecific interactions (identified from multiple IgG control replicates)
are removed. ET= endocrine therapy. (F) Venn diagram displays AIB1-
interacting proteins identified in MCF7 and LetR. G MS-ARC plot
shows AIB1-associated proteins specific to LetR cells. The AIB1-
associated proteins are clustered according to molecular function, and the
length of the line represents the Mascot score. Proteins of interest are
highlighted with enlarged bold text. AIB1 is displayed in the MS-ARC
plot as the immunoprecipitated protein of interest. (H) Plot of the Gene
Ontology (GO) molecular function enrichment test for the LetR only
AIB1 associated proteins (hypergeometric test, P-adj ≤ 0.05).
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parental MCF7 cells with a forced overexpression of CYP19
and long-term treatment with letrozole [2, 5].
In transient knockdowns in estrogen deprived LetR cells,
loss of AIB1 inhibited classic mechanism of epithelial
tumorigenicity including cell viability, mammosphere for-
mation and putative stemness (Fig. S4C). To elucidate the
aberrant global transcriptional program regulated by AIB1,
we undertook RNA-seq analysis in endocrine resistant LetR
cells and endocrine sensitive MCF7 cells, in the presence and
absence of AIB1 under estrogen deprivation (Figs. 4B; S4D,
E; Table S4, 5). Sixty-one AIB1 differentially regulated genes
were identified as unique to endocrine resistant tumor cells
(logfc ≥ 1.5; Padj ≤ 0.05) (Fig. 4C, Table S6). Of interest this
gene set does not overlap with the previously identified AIB1
coactivated subset of ESR1 dysregulated genes [2]. MSigDB
Oncogenic signature analysis of the 61 AIB1-regulated genes
revealed enrichment in growth-promoting pathways pre-
viously associated with endocrine resistance including LTE2,
RAF, ERBB2, and MEK (Fig. 4D; Table S7).
To better understand the mechanism behind the endo-
crine resistant-specific gene programs regulated by AIB1 it
was important to define the AIB1 interactome in this setting.
We employed RIME AIB1 protein [22] in endocrine
resistant LetR cells and endocrine sensitive MCF7 cells,
both under estrogen deprived conditions (Fig. 4E). We
solely considered AIB1-interacting proteins that were
common in three out of three independent biological
replicates and not in IgG controls. This approach yielded
280 AIB1-interacting proteins in MCF7s and 310 AIB1-
interacting proteins in LetR cells (Fig. 4F; Table S8). ER
was not pulled out as an interacting partner of AIB1 in the
absence of estrogen, as has been described previously
[22, 23]. The estrogen-dependent AIB1-ER interaction was
verified using a standard Co-IP experiment in MCF7s (Fig.
S5A). One hundred and fourteen AIB1 interacting proteins
were found to be unique to LetR cells (Fig. 4F, G; Table
S9), including known pro-tumorigenic and pro-metastatic
proteins, such as MTA2, DEK, TRIM25, CCAR2, RAC1,
RUVB1, ACIN1.
To better understand the potentially divergent molecular
processes potentiated and mediated by AIB1 and to prioritize
essential genes, we performed molecular function pathway
enrichment analysis of the interacting proteins unique to LetR.
Cell adhesion and cadherin binding, key constituents of epi-
thelial to mesenchymal transition (EMT), were amongst the
top-ranked AIB1 interacting proteins (Fig. 4H, Table S10).
Consistent with this observation, KEGG pathway analysis of
differentially expressed genes (DEGs) from our RNAseq
studies revealed that endocrine resistant specific DEGs were
also enriched for a number of metastases promoting EMT
pathways (e.g., ECM-receptor interaction, Rap1 signaling,
axon guidance, focal adhesion and cell adhesion molecules)
(Fig. S5B, C; Table S11, S12). Further clinical relevance of
the endocrine resistant AIB1 cell adhesion/cadherin binding
interactome was examined in the same cohort of metastatic
ER+ endocrine-treated breast cancer patients. Comprehensive
progression-free survival analysis for the 16 top-ranked AIB-1
interacting proteins demonstrated that elevated levels of 11/16
genes associated with worse PFS (Fig. S5D; Table S13).
These findings suggest a role for AIB1 in mediating a pro-
metastatic EMT program in ER+ breast cancer.
AIB1 interactome as a regulator of pro-EMT
phenotype
In the context of endocrine resistance, little is known about
the function of AIB1 in regulating EMT and pro-metastatic
phenotype. Initiation and establishment of metastasis is
dependent on EMT associated transcription factors (TFs)
and key EMT factors including the prototypic cell adhesion
molecule, e-cadherin (encoded by CDH1) [24, 25]. Here,
we find that AIB1 differentially regulates gene expression
of a number of EMT drivers identified above with sup-
pression of CDH1 and up regulation key EMT TFs
including SLUG and TWIST (Fig. 5A). Utilizing two
independent siRNA against AIB1, we confirm these
alterations at protein level with a reduction in levels of N-
cadherin, Vimentin, Snail and an increase in E-cadherin
(Fig. 5B).
Genome-wide analysis of the transcriptionally activat-
ing H3K4me3 mark in endocrine resistant metastatic
tumors, revealed altered binding profiles in poor outcome
patient tumors for EMT marker genes profiled in 5 A and
genes encoding the top-ranked AIB1 interacting cell
adhesion and cadherin binding proteins (Fig. S6A, B).
These data prompted a further investigation into tran-
scriptional regulation of pro-EMT pathways in endocrine
resistance and in particular unexpected CDH1 repression
by the coactivator AIB1.
AIB1 IP ChIP-qPCR revealed that AIB1 preferentially
bound to the promoter region of CDH1 in LetR cells when
compared to MCF7 cells, supporting the enriched cell
adhesion/cadherin binding phenotype identified in AIB1-
interactome in LetR only, but not MCF7 cells (Fig. 5C).
Interestingly, ER itself was previously shown to bind
CDH1 and repress E-cadherin expression in estrogen sti-
mulated MCF7 cells [26]. This was confirmed by identi-
fying ESR1 as the most frequent breast cancer cell-related
factor binding to the CDH1 promoter sequence using the
DB cistrome toolkit [27] (Table S14). However, ER IP
followed by ChIP-qPCR demonstrated no ER binding to
CDH1 promoter in the endocrine resistant LetR under the
same conditions. In contrast and in agreement with pre-
viously published studies, estrogen stimulated ER binding
to CDH1 in endocrine sensitive MCF7 cells was evident
(Fig. S6 C, D).
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Although previously reported for members of the
nuclear coactivator family SRC-1 and SRC-2, transcrip-
tional repression potentiated by AIB1 has yet to be fully
elucidated [19, 28–32]. Accumulating data indicates that
AIB1 typically acts as a primary recruiter of additional
coregulators that execute its transcriptional regulation as
evidenced in its recruitment of activators, p300/CBP and
CARM1 [33]. Here we looked for potential AIB1
interactors detected by RIME that could be executing
AIB1-mediated repression of CDH1. A number of chro-
matin binding proteins with known repressive function,
including MTA2 previously identified to repress both
ESR1 and CDH1, were identified as AIB1 partners
[34, 35]. To further support the endogenous interaction
between AIB1 and MTA2, nuclear protein from MCF7
and LetR cells, under estrogen-starved conditions, was
Fig. 5 AIB1 induces and regulates EMT and CDH1. A qRT-PCR
analysis of selected EMT markers gene expression in the LetR cells
transiently transfected with either NT or AIB1 siRNA. B Western blot
analysis of AIB1, B-ACTIN, and EMT markers N-cadherin, E-cad-
herin, Vimentin, Snail and Slug. LetR cells were transfected with
either siNT-1, siNT-2, siAIB1-1, or siAIB1-2 and whole cell lysate
harvested. In total, 30 µg of protein was loaded per gel. C AIB1
Chromatin Immunoprecipitation (ChIP) assay in MCF7 and LetR cells
showing the differential recruitment of IP AIB1 to the CDH1 pro-
moter. CHIP-grade Rabbit IgG antibody was used as a control and data
are presented as % INPUT. D Co-Immunoprecipitation (CO-IP) of
AIB1 followed by western immunoblotting to detect the MTA2
interaction in nuclear extracts of LetR and MCF7 cells CHIP-grade
Rabbit IgG used as a control. Western blotting of MTA2 protein
expression in the nuclear lysates. E, F CO-IP of AIB1 in nuclear
extracts of endocrine resistant cell lines and PDX tumors followed by
immunoblotting for MTA2. CHIP-grade Rabbit IgG used as a control.
G MTA2 IP ChIP in MCF7 and LetR cells showing the differential
recruitment of MTA2 on the CDH1 promoter. Data are presented as %
INPUT. H CHIP-re-ChIP in LetR cells displaying relative fold
enrichment over control with AIB1-IP >MTA2-IP versus AIB1-IP >
IgG-IP. I CHIP-re-ChIP in LetR cells displaying relative fold enrich-
ment over control with MTA2-IP > AIB1-IP versus MTA2-IP > IgG-
IP. J MTA2 IP ChIP showing the recruitment of MTA2 on the CDH1
promoter in siNT-1 versus si-AIB1 LetR cels. Data are presented as %
INPUT. All experiments carried out under steroid starved conditions
with the exception of PDX tumors in (F). ChIP-grade Rabbit IgG used
as a control in ChIP, re-ChIP and Co-IP experiments. Western blot gel
images are cropped at the band of interest for clarity. No other bands
were detected in Co-IP gels. All experiments are representative of
three biologically independent replicates. In the case of PDX tumors
protein was pooled. Two-sided t-tests were used to calculate P values.
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evaluated by a standard coimmunoprecipitation (Co-IP)
experiment. AIB1 IP, followed by immunoblotting
against MTA2 demonstrated that MTA2 was consistently
and differentially coimmunoprecipitated with AIB1 in
LetR cells (Fig. 5D), thus confirming it as a potential
partner. The increased interaction between AIB1/MTA2
in LetR cells was independent of basal MTA2 expression
(Fig. 5C). Moreover, AIB1 IP, followed by immuno-
blotting against MTA2 confirmed AIB1/MTA2 interac-
tion in LY2-LUC, metastatic variant LY2-LUCBone_Mets
and LTED cells (Fig. 5E). This was also true in the case
of patient-derived tumors T638, HCI-05 and HCI-11 that
responded to AIB1 inhibition with SI-2 (Fig. 5F).
Similar to AIB1, MTA2 IP followed by ChIP-qPCR to
the CDH1 gene was found to be significantly enriched over
IgG in LetR cells and no binding was detected in MCF7
cells under the same conditions (Fig. 5G). Other identified
cofactors with known repressor activity do not bind to the
same region in LetR cells, as was the case with TRIM25
and HDAC2 (Fig. S6E). Analysis of publically available
AIB1 and MTA2 ChIP-seq data revealed majority DNA
binding events were shared with only 3% of the binding
peaks differentially expressed between AIB1 and MTA2
and a notable overlap with the AIB1 differentially regulate
genes identified in Fig. 4 (Supplementary Fig. 7, Supple-
mentary Table S15). The co-occupancy was corroborated
with a ChIP-reChIP in LetR cells utilizing AIB1-MTA2 and
MTA2-AIB1 sequential IPs. Re-ChIP-qPCR revealed that
AIB1-MTA2 binding to the CDH1 was significantly enri-
ched over AIB1-IgG (Fold Enrichment 4.7 over IgG, P=
0.025) in LetR cells (Fig. 5H). Similarly, a reverse MTA2-
AIB1 re-ChIP-qPCR demonstrated an enriched binding
over MTA2-IgG (Fold Enrichment 2.5 over IgG, P=
0.018), comparably less than AIB1-MTA2 (Fig. 5I).
Finally, an AIB1 knockdown with siAIB1-1 was sufficient
to reduce MTA2 binding to the CDH1 gene promoter
region (Fig. 5J).
In light of AIB1 and MTA2 co-operation, we assessed
the functional consequence of their expression in the LetR
model. Similarly, to AIB1, MTA2 was found to regulate
key EMT markers at protein level with an observed
reduction in levels of N-cadherin, Vimentin, Snail and an
increase in E-cadherin (Fig. 6A). We observe that both
AIB1 and MTA2 knockdowns resulted in significant
changes in both EMT-cellular phenotype and motility
competence (Fig. 6B, C, and D).
In order to gain further support for the role of the AIB1/
MTA2 complex in endocrine resistant progression and
regulation of cell adhesion/cadherin binding function, we
again analyzed the ER+ endocrine resistant metastatic PDX
models that had differential response to AIB1 inhibition and
contrasting expression of CDH1 protein E-Cadherin (Fig.
6E). In E-Cadherin negative T638 (E-Cadlow) AIB1, pAIB1
and MTA2 expression was significantly higher compared to
E-Cadherin (E-Cadhigh) expressing T347 model (AIB1, P=
0.021; pAIB1, P= 0.001 and MTA2, P= 0.002) (Fig. 6F).
E-Cadherin expression inversely correlated with AIB1 (r=
−0.9305, P= 0.007), pAIB1 (r=−0.9130, P= 0.011) and
MTA2 (r=−0.8684, P= 0.025) (Fig. 6G). Interestingly,
forced overexpression of AIB1 in the primary cell culture
derived from the T347 PDX (T347x) was sufficient to cause
a reduction in E-Cadherin protein expression (Fig. 6H).
Altogether, our data suggests that in endocrine resistant
tumors, under estrogen deprivation, AIB1 partners with pro-
metastatic proteins to drive disease progression through a
uniquely acquired AIB1-dependent transcriptome and
interactome enriched for adhesion and cadherin pathways.
Discussion
In addition to the selection of the critical resistance muta-
tions in PI3K/mTOR/AKT, ERBB2, cell cycle and ESR1
pathways described clinically, adaptations to endocrine
therapy may also involve transcriptional and epigenomic
reprogramming of key survival and pro-metastatic pathways
which are triggered as cells acquire resistance. Here, we
report that AIB1, in combination with MTA2, negatively
regulates the expression of key nodes of cell adhesion/
cadherin binding function. Consequently, this AIB1 medi-
ated adaptation fine-tunes the regulation of migratory/
growth potential of endocrine resistant cancer cells and
activates a pro-metastatic phenotype. Our data provides
evidence that AIB1 acts a survival factor in multiple
endocrine resistant metastatic breast cancer models where
AIB1 may also be a potential drug target [17, 36, 37]. We
demonstrate successful targeting of endocrine resistant
metastatic cell line and patient-derived tumors harboring
high AIB1 and pAIB1 expression while presenting evidence
of re-sensitization of resistant cells. Indeed, Gates et al. have
previously reported pharmacological inhibition of AIB1
with a small molecule inhibitor SI-2 alone may be enough
to re-sensitize resistant tumor to endocrine treatment in
ESR1 mutant tumors in vivo [18].
Accumulating evidence indicates that aberrant AIB1
expression is a key event in multiple tumor types and is a
regulator of tumor cell growth, survival, disease progres-
sion, and metastasis [6, 38]. Functionally, AIB1 executes its
role in breast cancer by transcriptionally coactivating ER,
even in the cases of treatment resistant mutant ER tumors
[18, 39]. However, unbiased interrogation of the AIB1
interactome described here, revealed a new role for AIB1 as
a facilitator of target gene repression in advanced endocrine
resistance. Similar roles for steroid receptor coregulators
have been described by our group and others [19, 28–
32, 40]. Collectively these data provide evidence for a
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previously under-appreciated function of the SRC cor-
egulator family in transcriptional suppression, broadening
their impact and extending their regulatory network to
promote metastasis.
Data presented in this study suggests that AIB1 con-
tributes to metastatic disease progression, at least in part,
independently of ER. This is pertinent considering the
reported ER-independent mechanism of therapy resistance
and the loss of ER expression reported in patient-matched
ER+ primary and metastatic tumor samples [2, 41, 42]. It
has been previously reported that AIB1 may function in the
absence of ER to promote tumorigenesis [43] and such
adaptations can result in the evolution of estrogen inde-
pendence and estrogen deprivation treatment resistance [2].
It is less clear whether these changes are associated with
resistance to selective ER degraders given that our experi-
mental system models estrogen deprivation, achieved
clinically via AI therapy. The ability of ER degraders to
activate similar AIB1-driven pro-metastatic re-
programming through these mechanisms may however be
likely given the discordance between ER and AIB1 func-
tions in metastatic tumors reported here.
This work describes a set of 114 AIB1 interacting
proteins unique to the AI resistant phenotype. AIB1
directly interacts and colocalizes with MTA2 to repress
E-cadherin expression thereby promoting EMT, migration
and pro-metastatic phenotype of estrogen deprived breast
cancer cells. Induction of EMT in concert with loss or
Fig. 6 AIB1 interactome as a regulator of pro-EMT phenotype.
A Western blot analysis of MTA2, B-ACTIN, and EMT markers N-
cadherin, E-cadherin, Vimentin, Snail and Slug. LetR cells were
transfected with either siNT-1, siNT-2, siMTA2-1, or siMTA2-2 and
whole cell lysate harvested. 30µg of protein was loaded per gel.
Western blot gel images are cropped at the band of interest for clarity.
B Light-phase microscopy images of LetR cells cellular characteristics
in the presence of two distinct siRNAs against AIB1 and MTA2. Cells
were steroid and serum-starved and then subsequently seeded in pre-
sence of serum. Representative images of an n= 3 biological repli-
cates taken 48 h after seeding (×20 magnification, scale bars represent
100 μm). C, D LetR cells were depleted of AIB1 or MTA2 using a two
independent siRNAs. Cellomics Cell Motility Kit was used to assess
individual cell movement in collagen in a 96-well plate after 24 h.
Representative images are shown as seen on the microscope after cells
were fixed and stained (×20 magnification, scale bars represent 20 μm).
All functional experiments were carried out under estrogen deprived
conditions. Image of treatment sensitive cell line MCF7 is shown for
comparison. Histogram shows mean migratory area per cell (μm.2). All
results in the figure are mean ± S.E.M., n= 3 (biologically indepen-
dent replicates) and two-sided t tests were used to calculate P values
(*P < 0.05; **P < 0.001, ***P < 0.0001). E Representative images of
E-Cadherin (E-Cad), AIB1, pAIB1Thr24, and MTA2 protein immu-
nohistochemistry (IHC) in PDX tumor T638- PDX (left panel) and
T347-PDX (right panel). All scale bars, 50 μm. F Scatter plot of IHC
scores (0–300) calculated in T638-PDX and T347-PDX (n= 3 mice
per PDX model; At least 500 cells were assessed in each case).
G Correlation plot comparing IHC scores in T638-PDX and T347-
PDX, assessing AIB1vCDH1, pAIB1vCDH1, and MTA2vCDH1.
H Western blot analysis of E-cadherin (E-Cad) protein expression
(from whole cell lysate) in the T347x primary culture cells transfected
with either empty pcDNA3.1 plasmid vector (Control) or pcDNA3.1
plasmid containing full-length AIB1 (AIB1_OVX). Gel images dis-
play AIB1, E-Cadherin (E-Cad) and B-Actin and are representative of
three biologically independent replicates.
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dysfunction of CDH1 is strongly linked with tumorigen-
esis and metastatic competence in numerous cancers [24].
Interestingly, AIB1 expression has previously correlated
negatively with E-cadherin in pancreatic cancer, lung and
MMTV-PyMt breast cancer mouse models [8, 36, 44].
Negative correlation between AIB1 and E-Cadherin will
need to be confirmed in larger proteomic datasets con-
sidering both ductal and lobular breast cancers. However,
here we provide a novel molecular mechanistic link
between AIB1 and CDH1 relevant to the pro-metastatic
phenotype in endocrine resistance.
MTA2 is a member of the Mi-2/nucleosome remodeling
and deacetylase (NuRD) complex which was previously
shown to be important in mediating migration and
anchorage-independent growth [34, 45]. Estrogen depen-
dent interaction between AIB1 and MTA2 have previously
been identified in screening studies in endocrine sensitive
breast cancer cells [23], although the mechanism of action
in the context of endocrine resistant tumors has not been
described. In the resistant phenotype, it is feasible that in
addition to the MTA2 having its own set of pre-marked
DNA targets, AIB1 differentially recruits MTA2 to a spe-
cific set of targets pertinent to endocrine resistant cells. This
raises the possibility that altered AIB1 interactome activity
may result in coordinated resistant cell re-programming to
promote the metastatic phenotype.
Although, we have focused on AIB1/MTA2 activity in
the context of CDH1 repression, it is likely that AIB1
recruits other transcriptional coregulators to carry out its
pro-EMT function, indeed several known chromatin remo-
delers were also detected to directly interact with AIB1. In
addition, although our investigation centers on the cell
adhesion and cadherin pathways as the most enriched in
resistant cells, components of multiple biological signaling
pathways are enriched in the resistant cell specific AIB1
interactome. As such, AIB1 may coordinate multiple sig-
naling pathways and biological processes that can con-
tribute to alternative functions that support metastatic
growth and which should be addressed in the future.
Our study is not without limitations. The precise
dynamics of the AIB1 chromatin colocalization with MTA2
has yet to be explored. Here, through ChIP-re-ChIP
experiments we have demonstrated colocalization of AIB1
and MTA2 specifically on the CDH1 promoter and pre-
sented evidence of dependence of MTA2 binding on AIB1.
Whether AIB1 interacts with the entire protein complex
simultaneously or if it sequentially recruits various cor-
egulators to modulate transcription as described previously
requires further investigation beyond the scope of this study
[33]. Furthermore, it remains to be determined whether
AIB1 recruitment alone, while necessary, is sufficient for
the repressive function demonstrated here.
Data reported here present a mechanistic link between
the aberrant expression of AIB1, its interactome and their
contribution to breast cancer progression in endocrine
resistance. Overall, these results provide new mechanistic




Gene expression datasets on endocrine treated breast tumors
were downloaded from NCBI GEO and previously pub-
lished RNA-sequencing studies [15, 41, 46]. cBioPortal
[47] was utilized to download metastatic breast cancer
mutational and the Metabric data. Cistrome data browser
(Cistrome DB) [27] was utilized to access ChIP-seq data
[16]. Full details on all the analysis is provided in the
Supplementary Methods File.
Cell culture and functional assays
MCF7 cells were sourced from ATCC. Culture conditions
and establishment protocols for the various endocrine
resistant models (LetR [2], T347x [19], LTED [48], LCC9,
and LY2 [20]) have been previously described. LetR cells
were established from MCF7 cells stably overexpressing
CYP19 and long-term treated in the presence of letrozole.
All functional assays are described in the Supplementary
Methods File.
Animal studies
Full details on establishment of in vivo models is provided
in the Supplementary Methods File.
Animal studies were performed in accordance with all
the relevant ethical animal research regulations and were
approved by Research Ethics Committee (#1045bbb) under
a license from the HPRA. PDX Written and informed
consent was acquired prior to collection of all patient tumor
tissue under RCSI Institutional Review Board approved
protocol (#13/09;ICORG09/07). PDX samples were estab-
lished as described previously [49].
Patient-derived tumor explants (PDTEs)
Metastatic PDX tissue was cut and dissected into 2-4mm3
tumor fragments and placed on 1 cm3 hemostatic gelatin
dental sponges (Vetspon, Novartis) pre-soaked with human
mammary epithelial media as described previously [50].
Full details provided in Supplementary Methods File.
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RNA-sequencing
RNA-seq was carried out in biological triplicate in MCF7
and LetR cells comparing siNT versus siAIB1. RNA was
subjected to 100bpPE sequencing using the BGISEQ 500
platform.
Protein profiling
Full details on protein extraction, immunoprecipitation,
western blotting, and immunohistochemistry are provided
in the Supplementary Methods File.
RIME
RIME protocol was utilized to purify endogenous AIB1 and
identify interacting proteins. Briefly steroid depleted cells
were cross-linked, chromatin extracted and immunopreci-
pitated with either AIB1 antibody (10 µg; Santa Cruz; sc-
25742) or negative control IgG (10 µg; Diagenode;
C15410206) as previously described [22]. Full details are
provided in the Supplementary Methods File.
Chromatin immunoprecipitation (ChIP)
Steroid starved cells were fixed, crosslinked and ChIP was
carried out as described in Supplementary Methods. ChIP-
re-ChIP includes an additional elution step after first IP pull
followed by the sequential ChIP pull with either antibody of
interest or IgG [19].
Statistical analysis
Wilcoxon-signed ranked tests were used with log2-
normCPM values in single gene expression queries. Dif-
ferences between two groups were analyzed by two-tailed t
test (Gaussian) or Mann–Whitney U-test (nonparametric)
and were considered statistically different if P < 0.05. Sur-
vival data was calculated with the log-rank test. No statis-
tical method was used to pre-determine sample size.
Data availability
All data is included in the article and in its Supplementary
Files. Sequencing data is deposited in the Gene Expression
Omnibus under the accession number GSE158095.
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